MetLife director granted 721 deferred stock shares

Kennard William E reported acquisition or exercise transactions in this Form 4 filing.

Rhea-AI Filing Summary

Kennard William E reported acquisition or exercise transactions in this Form 4 filing.

MetLife Inc. director William E. Kennard received a grant of 721 shares of MetLife common stock on April 1, 2026, as part of non‑management director compensation. The shares were valued at $71.17 each and he elected to defer receipt under the MetLife Deferred Compensation Plan for Non-Management Directors.

Following this award, Kennard is reported as beneficially owning 46,501 shares of MetLife common stock directly, and an additional 10 shares are held indirectly in the MetLife Policyholder Trust that holds stock allocated to eligible policyholders.

Insider Trade Summary

Grant/Award: 721 shares

Grant/Award 2 txns

Insider Kennard William E

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	721	$71.17	$51K
holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 46,501 shares (Direct); Common Stock — 10 shares (Indirect, By the MetLife Policyholder Trust)

Footnotes (2)

1. F1. MetLife, Inc.'s non-management director compensation arrangements pay a portion of non-management director retainer fees in MetLife, Inc. common stock. The director elected to defer receipt of these shares under the MetLife Deferred Compensation Plan for Non-Management Directors.
2. F2. Shares held in trust under the MetLife Policyholder Trust established to hold shares of common stock allocated to eligible policyholders of Metropolitan Life Insurance Company, a wholly-owned subsidiary of MetLife, Inc.

Key Figures

Director stock grant: 721 shares Grant valuation price: $71.17 per share Direct holdings after grant: 46,501 shares +1 more

4 metrics

Director stock grant 721 shares Common stock award on April 1, 2026

Grant valuation price $71.17 per share Value used for 721-share director grant

Direct holdings after grant 46,501 shares Common stock directly held after April 1, 2026 grant

Indirect holdings in trust 10 shares Common stock held via MetLife Policyholder Trust

Key Terms

MetLife Deferred Compensation Plan for Non-Management Directors, MetLife Policyholder Trust, non-management director compensation arrangements, beneficially owning

4 terms

MetLife Deferred Compensation Plan for Non-Management Directors financial

"The director elected to defer receipt of these shares under the MetLife Deferred Compensation Plan for Non-Management Directors."

MetLife Policyholder Trust financial

"Shares held in trust under the MetLife Policyholder Trust established to hold shares of common stock allocated"

non-management director compensation arrangements financial

"MetLife, Inc.'s non-management director compensation arrangements pay a portion of non-management director retainer fees in MetLife, Inc. common stock."

beneficially owning financial

"Following this award, Kennard is reported as beneficially owning 46,501 shares of MetLife common stock directly"

FAQ

What did MetLife (MET) director William E. Kennard report in this Form 4?

Director William E. Kennard reported receiving a grant of 721 MetLife common shares as part of non-management director compensation. The award is a share-based fee, not an open-market stock purchase or sale, and reflects routine board compensation practices at MetLife Inc.

At what price were William E. Kennard’s MetLife (MET) director shares valued?

The 721 MetLife common shares granted to William E. Kennard were valued at $71.17 per share. This value is used to determine the size of the stock-based retainer component under MetLife’s non-management director compensation arrangements for its board members.

How many MetLife (MET) shares does William E. Kennard hold after this transaction?

After the grant, William E. Kennard is shown as directly holding 46,501 MetLife common shares. In addition, 10 shares are held indirectly in the MetLife Policyholder Trust, which holds stock allocated to eligible policyholders of Metropolitan Life Insurance Company.

Did William E. Kennard buy or sell MetLife (MET) shares on the market?

The filing shows a grant of 721 MetLife shares as director compensation, classified as a grant or award acquisition. It does not report an open-market purchase or sale, but rather stock-based fees that Kennard elected to defer under a deferred compensation plan.

What is the MetLife Deferred Compensation Plan for Non-Management Directors?

The MetLife Deferred Compensation Plan for Non-Management Directors allows directors to defer receipt of common stock granted as part of their fees. In this filing, William E. Kennard elected to defer the 721-share grant into this plan instead of receiving shares immediately.

What is the MetLife Policyholder Trust mentioned in the MET Form 4?

The MetLife Policyholder Trust holds MetLife common stock allocated to eligible policyholders of Metropolitan Life Insurance Company. In this filing, 10 shares attributed to William E. Kennard are held in this trust, representing a small indirect ownership position separate from his direct holdings.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 04/03/2026 - 04:05 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Kennard William E

(Last) (First) (Middle)

METLIFE, INC.

200 PARK AVENUE

(Street)

NEW YORK NEW YORK 10166

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
METLIFE INC [ MET ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	04/01/2026		A(1)		721	A	$71.17	46,501	D
Common Stock								10	I	By the MetLife Policyholder Trust(2)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. MetLife, Inc.'s non-management director compensation arrangements pay a portion of non-management director retainer fees in MetLife, Inc. common stock. The director elected to defer receipt of these shares under the MetLife Deferred Compensation Plan for Non-Management Directors.

2. Shares held in trust under the MetLife Policyholder Trust established to hold shares of common stock allocated to eligible policyholders of Metropolitan Life Insurance Company, a wholly-owned subsidiary of MetLife, Inc.

Remarks:

	/s/ Taylor McInerney Jansen, Attorney-in-fact	04/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)